metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcohol...
Journal Information
Vol. 19. Issue S1.
Abstracts of the 2020 Annual meeting of the Mexican Association of Hepatology (AMH) – XV Congreso Nacional de Hepatología (23-25 de julio)
Pages 9 (September 2020)
Share
Share
Download PDF
More article options
Vol. 19. Issue S1.
Abstracts of the 2020 Annual meeting of the Mexican Association of Hepatology (AMH) – XV Congreso Nacional de Hepatología (23-25 de julio)
Pages 9 (September 2020)
19
Open Access
Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model
Visits
666
J. Gutiérrez-Cuevas1, A. Sandoval-Rodríguez1, C. Monroy-Ramírez1, A. Santos-García2, J. Armendáriz-Borunda1,2
1 University of Guadalajara, Institute for Molecular Biology in Medicine and Gene Therapy, Department of Molecular Biology and Genomics, CUCS, Jalisco, Mexico
2 Tecnologico de Monterrey, Campus Guadalajara, Jalisco, México
This item has received

Under a Creative Commons license
Article information
Full Text

Background and aim: Obesity is associated with insulin resistance, nonalcoholic steatohepatitis (NASH) and myocardial fibrosis. Peroxisome proliferator-activated receptors (PPARs) regulate carbohydrate and lipid metabolism; improving insulin sensitivity, triglyceride levels, inflammation and oxidative stress. Pirfenidone has anti-inflammatory, antioxidant and antifibrotic effects. Aim, we investigated the molecular effects of prolonged-release pirfenidone (PR-PFD) in ventricular tissue of male C57BL/6J mice with NASH.

Material and methods: All experiments were performed in compliance with the guidelines of the bioterium-CUCS Research Committee at the University of Guadalajara and National Institutes of Health (NIH). Five-week-old mice were fed with normal diet (ND, 18% kcal from fat, n=5) and high-fat/high-carbohydrate (HFHC, 60% kcal from fat, plus 42g/L: 55% fructose y 45% sucrose in water, n=10) diet for 16 weeks of feeding. At 8 week, five mice with HFHC diet were administered PR-PFD (350mg/kg/day). We assessed insulin resistance, oil red o, hematoxylin-eosin, Masson's trichrome and picrosirius staining, western blot, immunohistochemistry, RT-qPCR and data by SPSS.

Results: Mice showed NASH with insulin resistance, myocardial steatosis and fibrosis, which were prevented by PR-PFD. Ventricular tissue of HFHC mice showed increased TNF-α, Nrf2, Desmin, Tgfβ1, Timp1, Collagen-I, Collagen-III, mRNA levels, including NF-kB, Nrf2, α-SMA, Troponin-I, Acox1, Cpt1A and Lxrα protein levels compared to the ND ventricular tissues (P0.05). PR-PFD treatment decreased these genes overexpressed by HFHC diet (P0.05). PR-PFD overexpressed the Pgc1a mRNA levels and Pparα, Pparγ, Acox1 and Cpt1A protein levels (P0.05).

Conclusions: PR-PFD prevents the cardiac steatosis and fibrosis by sobreexpressing Pparα, Pparγ, Acox1 y Cpt1A proteins. PR-PFD is a promising drug for the treatment of cardiac fibrosis induced by NASH.

This work was supported by “Fondo de Desarrollo Científico de Jalisco (FODECIJAL, 8149-2019 and 7941-2019)” and by “Consejo Nacional de Ciencia y Tecnología (CONACYT, 259096)”.

Conflicts of interest: The authors have no conflicts of interest to declare.

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2020.08.012
No mostrar más